SCHEMBL25751514

SCHEMBL25751514

COC(=O)c1ccc(OC)c(-c2ncc(F)cn2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.50
KMT2A Q03164 5/20 0.46
ABL1 P00519 1/20 0.44
MAPK1 P28482 3/20 0.43
MEN1 O00255 3/20 0.43
LMNA P02545 2/20 0.42
HTT P42858 2/20 0.42
RAB9A P51151 1/20 0.42
ALPL P05186 2/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
XDH P47989 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
KDM1A O60341 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
CTSA P10619 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30957336 0.79 MAOB (0.42) LMNAHTTCTSAALDH1A1
SCHEMBL25751771 0.77 MAPT (0.50) MAPTKMT2AMEN1LMNAHTT
SCHEMBL20659158 0.76 L3MBTL1 (0.35) ABL1MAPK1LMNAHTTALDH1A1
SCHEMBL30957312 0.76 NPC1 (0.51) MAPTKMT2AMAPK1MEN1LMNA
SCHEMBL30855384 0.76 RECQL (0.49) KMT2AABL1MEN1LMNARAB9A
SCHEMBL29196619 0.76 RECQL (0.49) KMT2AABL1MEN1LMNARAB9A
SCHEMBL3210274 0.76 ADORA3 (0.48) MAPTKMT2AMAPK1MEN1LMNA
SCHEMBL17559286 0.75 ABL1 (0.61) MAPTKMT2AABL1ALPLKDM1A
SCHEMBL31500179 0.75 POLB (0.46) MAPTMAPK1HTTRAB9ACTSA
SCHEMBL13276414 0.75 AR (0.57) MAPTKMT2AABL1MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
EP-4448514-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Lynk Pharmaceuticals Co. Ltd. (CN) 2024-10-23 EP disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 MAPT 908/4885KMT2A 242/4885ABL1 6/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 MAPT 908/4885KMT2A 242/4885ABL1 6/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 MAPT 908/4885KMT2A 242/4885ABL1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.